US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Spero Therapeutics Inc.

0.7542

+0.01421.92%

Post-market: 0.75420.00000.00%17:33 EDT

Volume:35.94K

Turnover:27.62K

Market Cap:42.16M

PE:-0.59

High:0.7860

Open:0.7400

Low:0.7400

Close:0.7400

Loading ...

Overview Company News Filings

Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock?

Spero Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Mirum Shares Surge More Than 90% in 6 Months: Here's Why

Grifols Stock Declines After Brookfield Drops Buyout Offer

ODAC to Discuss Exelixis' Application for Cabometyx Label Expansion

NTLA Up as FDA Grants RMAT Status to Genome-Editing Therapy

Exelixis Stock Surges 25% in a Month: Time to Buy or Sell?

HALO Withdraws Acquisition Bid for EVO, Reaffirms '24 View, Stock Up

Corcept Shares Rise More Than 60% in Three Months: Here's Why

JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer

PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer

SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study

Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%

FATE Presents Encourgaing Data From Lupus Study, Stock Gains

CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC

Spero Therapeutics Cut to Hold From Buy by TD Cowen

CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC

TD Cowen downgrades Spero Therapeutics (SPRO) to a Hold

Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates

BRIEF-Spero Therapeutics Q3 EPS USD -0.32

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SPRO/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SPRO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPRO\",,,,,undefined,":{"symbol":"SPRO","market":"US","secType":"STK","nameCN":"Spero Therapeutics Inc.","latestPrice":0.7542,"timestamp":1744920000000,"preClose":0.74,"halted":0,"volume":35943,"hourTrading":{"tag":"盘后","latestPrice":0.7542,"preClose":0.7542,"latestTime":"17:33 EDT","volume":4,"amount":2.94,"timestamp":1744925595236},"delay":0,"floatShares":41896552,"shares":55900641,"eps":-1.27,"marketStatus":"Market Closed","change":0.0142,"latestTime":"04-17 16:00:00 EDT","open":0.74,"high":0.786,"low":0.74,"amount":27620.7074598,"amplitude":0.062162,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.27,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1509595200000,"exchange":"NASDAQ","adjPreClose":0.74,"postHourTrading":{"tag":"盘后","latestPrice":0.7542,"preClose":0.7542,"latestTime":"17:33 EDT","volume":4,"amount":2.94,"timestamp":1744925595236},"volumeRatio":0.16367411811174443,"impliedVol":0.0019,"impliedVolPercentile":0.3227},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPRO\",,,,,undefined,":{"symbol":"SPRO","floatShares":41896552,"roa":"-30.93%","roe":"-89.62%","lyrEps":-1.268849,"volumeRatio":0.16367411811174443,"shares":55900641,"dividePrice":0.06,"high":0.786,"amplitude":0.062162,"preClose":0.74,"low":0.74,"week52Low":0.5052,"pbRate":"0.91","psRate":"0.88","week52High":1.72,"institutionHeld":0.1648,"latestPrice":0.7542,"eps":-1.27,"divideRate":0.079554,"volume":35943,"delay":0,"ttmEps":-1.27,"open":0.74,"prevYearClose":1.03,"prevWeekClose":0.6,"prevMonthClose":0.72,"prevQuarterClose":0.72,"fiveDayClose":0.5775,"twentyDayClose":0.7776,"sixtyDayClose":0.874},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SPRO\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2488957588","title":"Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2488957588","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488957588?lang=en_us&edition=fundamental","pubTime":"2024-12-03 02:19","pubTimestamp":1733163540,"startTime":"0","endTime":"0","summary":"Shares of Allogene Therapeutics ALLO have lost nearly 23% year to date, underperforming the industry’s 7.0% decline. The stock has also underperformed the sector and the S&P 500 during the same period, as shown in the chart below. ALLO’s shares are trading below the 50 and 200-day moving averages.ALLO Stock Underperforms Industry, Sector & S&P 500. The decline in stock price can be attributed to the strategic changes in Allogene’s pipeline, announced at the start of this year. This delayed management’s plans to bring cema-cel, its lead pipeline drug, to the market by at least a couple of years.Let’s dig into the stock’s prospects.ALLO Explores Lead Drug’s Potential as First-Line LBCL Therapy. Allogene is also planning to explore the potential of allogeneic CAR-T cell therapies in autoimmune diseases. In this regard, it plans to start an early-stage study with a new candidate, ALLO-329, in lupus/systemic lupus erythematosus  indication by first-quarter 2025 and expects to have proof-of-","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/allogene-therapeutics-loses-23-date-181900263.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPRO","ALLO","CSTL","SLE","RCC","BK4505","BK4196","LENZ","BK4139","BK4077"],"gpt_icon":0},{"id":"2488209486","title":"Spero Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2488209486","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488209486?lang=en_us&edition=fundamental","pubTime":"2024-12-02 19:35","pubTimestamp":1733139300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SPRO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 02, 2024 06:35 ET (11:35 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","SPRO"],"gpt_icon":0},{"id":"2487562165","title":"Mirum Shares Surge More Than 90% in 6 Months: Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2487562165","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487562165?lang=en_us&edition=fundamental","pubTime":"2024-11-29 22:59","pubTimestamp":1732892340,"startTime":"0","endTime":"0","summary":"Shares of Mirum Pharmaceuticals, Inc. MIRM have rallied 90.9% in the past six months compared with the industry’s increase of just 1.1%.The company’s lead product is Livmarli , an orally administered ileal bile acid transporter  inhibitor approved for the treatment of cholestatic pruritus in patients with Alagille syndrome worldwide.In March 2024, the FDA approved Livmarli for the treatment of cholestatic pruritus in patients aged five years and older with progressive familial intrahepatic cholestasis , a rare genetic disorder that causes liver failure.Livmarli sales have been rising steadily since its approval and launch worldwide.The majority of Mirum’s revenues are now being driven by Livmarli. In the first nine months of 2024, Livmarli generated sales worth $149.2 million, up 48.7% on a year-over-year basis. The continued demand for Livmarli is driving the top line and the momentum is expected to continue in the future quarters.Mirum recently initiated the phase III EXPAND study, w","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mirum-shares-surge-more-90-145900658.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4505","MIRM","CSTL","SPRO","BK4196","IMCR","BK4139"],"gpt_icon":0},{"id":"2487934538","title":"Grifols Stock Declines After Brookfield Drops Buyout Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2487934538","media":"Zacks","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487934538?lang=en_us&edition=fundamental","pubTime":"2024-11-28 23:02","pubTimestamp":1732806120,"startTime":"0","endTime":"0","summary":"Shares of Grifols GRFS lost over 7% on Wednesday after the company announced that Canada-based Brookfield Asset Management has withdrawn its plan to acquire it.Both parties likely failed to arrive at a common ground over the company's value. Last week, Grifols’ board refused to endorse Brookfield’s offer to acquire its outstanding share capital for 6.45 billion . Per management, the valuation “significantly undervalues the company’s fundamental prospects and its long-term potential.”This announcement puts an end to months of negotiations between Grifols and Brookfield, which, along with key shareholders of Grifols, had expressed its intent for a potential takeover in July. These key shareholders are members of the Grifols family as well as the founders of the company. Per a Bloomberg article, the Grifols family owns about a third of the company.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/grifols-stock-declines-brookfield-drops-150200692.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","SPRO","CTMX","BK4135","BK4196","CSTL","GRFS","BK4139","BAM","BK4585"],"gpt_icon":0},{"id":"2486803311","title":"ODAC to Discuss Exelixis' Application for Cabometyx Label Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2486803311","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486803311?lang=en_us&edition=fundamental","pubTime":"2024-11-28 00:29","pubTimestamp":1732724940,"startTime":"0","endTime":"0","summary":"Exelixis, Inc. EXEL announced that its supplemental new drug application  for cabozantinib will be discussed at an Oncologic Drugs Advisory Committee  meeting in March 2025.The sNDA is seeking approval for the drug to treat adults with previously treated advanced pancreatic neuroendocrine tumors  and advanced extra-pancreatic NET .Exelixis’ shares have surged 48.9% year to date against the industry’s decline of 7.8%.The company was notified of the update on the ODAC meeting by the FDA. ODACs mostly review and evaluate data regarding the safety and effectiveness of marketed and investigational human drug products for use in the treatment of cancer and make recommendations to the Commissioner of Food and Drugs.Per EXEL, the planned ODAC meeting is not related to the currently approved indications for Cabometyx in the United States.In August 2024, the FDA granted cabozantinib orphan drug designation for the treatment of pNET and assigned a target action date of April 3, 2025.EXEL’s Effort","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cYhdSHZ3kDYVQNhcMTsM_w--~B/aD0zOTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4a0e141116a5c1fff5e57140486a1890","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cYhdSHZ3kDYVQNhcMTsM_w--~B/aD0zOTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4a0e141116a5c1fff5e57140486a1890"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/odac-discuss-exelixis-application-cabometyx-162900490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BFTCPJ56.SGD","EXEL","SPRO","SG9999001440.SGD","LU1066051225.USD","SG9999001176.SGD","BK4139","BK4550","LU1037948541.HKD","LU1989771016.USD","LU1116320737.USD","LU2023250843.SGD","MRK","IE00BSNM7G36.USD","LU0861579265.USD","SG9999014542.SGD","LU0058720904.USD","LU1037948897.HKD","HCC","LU2361045086.USD","SG9999001176.USD","LU2089984988.USD","LU0203345920.USD","BK4006","SG9999014567.USD","IE00BBT3K403.USD","BK4195","LU1093756325.SGD","LU1291159041.SGD","LU0265550359.USD","LU0238689110.USD","LU0234572021.USD","BK4007","LU0965509010.AUD","LU0211331839.USD","PFS","LU1934455863.HKD","IE0002141913.USD","LU0965509101.SGD","LU2361044949.HKD","RCC","LU1061106388.HKD","CSTL","IE00BN8TJ469.HKD","LU1989772840.SGD","LU2023250504.SGD","LU2361044865.SGD","DTC","LU0122379950.USD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2486886490","title":"NTLA Up as FDA Grants RMAT Status to Genome-Editing Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2486886490","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486886490?lang=en_us&edition=fundamental","pubTime":"2024-11-26 23:30","pubTimestamp":1732635000,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics, Inc. NTLA announced that the FDA has granted the Regenerative Medicine Advanced Therapy  designation to its investigational in vivo genome-editing candidate, Nexiguran ziclumeran .The regulatory body granted the RMAT designation to nex-z for the treatment of hereditary transthyretin  amyloidosis with polyneuropathy .The RMAT designation provides the candidate with increased opportunities to meet FDA officials, as well as arrange early meetings to discuss potential surrogate or intermediate endpoints. It opens up early interactions between the FDA and sponsors to facilitate accelerated approval and potential priority review of a product’s biologics license application .Shares of Intellia were up 3.4% yesterday following the announcement of the news. However, the stock has plunged 51.6% so far this year compared with the industry’s decline of 9%.Earlier this month, the FDA cleared Intellia’s investigational new drug  application for initiating the pivotal phase III","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.WQmSb1MJO1_eLnmBVS1zA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.WQmSb1MJO1_eLnmBVS1zA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ntla-fda-grants-rmat-status-153000433.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LU0053666078.USD","LU0114720955.EUR","LU0882574055.USD","LU2362540622.SGD","LU1861558580.USD","LU1861559042.SGD","LU0109394709.USD","LU0289739699.SGD","NTLA","LU2362541273.HKD","BK4588","LU0320765992.SGD","LU2023250504.SGD","SPRO","BK4556","LU2362541513.USD","LU2468319806.SGD","CSTL","LU2089984988.USD","LU1917777945.USD","BK4196","BK4585","BK4535","LU0889565916.HKD","LU0058720904.USD","REGN","LU2106854487.HKD","LU1974910355.USD","LU0823416689.USD"],"gpt_icon":0},{"id":"2486517140","title":"Exelixis Stock Surges 25% in a Month: Time to Buy or Sell?","url":"https://stock-news.laohu8.com/highlight/detail?id=2486517140","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486517140?lang=en_us&edition=fundamental","pubTime":"2024-11-26 02:25","pubTimestamp":1732559100,"startTime":"0","endTime":"0","summary":"Shares of Exelixis, Inc. EXEL have surged 25% in a month against the industry’s decline of 4.9%. The stock has also outperformed the sector and the S&P 500 Index in this timeframe.The outperformance can be attributed to better-than-expected third-quarter results. The company also raised its annual guidance.Exelixis has been a consistent outperformer of late on the back of the strong performance of its lead drug Cabometyx and encouraging pipeline progress.Net revenues were $539.5 million, which easily beat the Zacks Consensus Estimate of $491 million. The top line surged 14.3% year over year.Exelixis also intends to submit an sNDA with the FDA later this year for cabozantinib, in combination with Tecentriq , for metastatic castration-resistant prostate cancer.Another promising candidate in Exelixis’ pipeline is zanzalintinib, a next-generation oral. Enrollment has been completed in the late-stage STELLAR-303 study evaluating zanzalintinib, in combination with Tecentriq, compared with re","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0.VF5p.GUKhgU24gMni2XA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59a827b8514d5d6d47690daa5eb16f24","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0.VF5p.GUKhgU24gMni2XA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59a827b8514d5d6d47690daa5eb16f24"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exelixis-stock-surges-25-month-182500523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999001440.SGD","BK4196","BK4585","LU0861579265.USD","LU0208291251.USD","LU0965509283.SGD","LU1934455194.USD","LU2089984988.USD","IE00BLSP4239.USD","IE00BSNM7G36.USD","LU0211331839.USD","BK4559","LU1116320737.USD","LU1989772923.USD","LU1983299246.USD","LU2023250843.SGD","BK4534","MRK","IE00B2B36J28.USD","LU2361044949.HKD","LU0203345920.USD","LU1066051811.HKD","LU1093756168.USD","LU1066051225.USD","LU1989771016.USD","LU1116320901.HKD","IE0002141913.USD","LU1974910355.USD","LU1023059063.AUD","LU0965509101.SGD","BK4533","EXEL","SG9999015341.SGD","CSTL","LU0289739699.SGD","BK4139","SG9999015358.SGD","SPRO","IE000M9KFDE8.USD","BK4550","RCC","SG9999002232.USD","LU0122379950.USD","IE0009355771.USD","LU2106854487.HKD","LU0106261372.USD","LU0265550946.USD","LU1941712348.USD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2486058699","title":"HALO Withdraws Acquisition Bid for EVO, Reaffirms '24 View, Stock Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2486058699","media":"Zacks","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486058699?lang=en_us&edition=fundamental","pubTime":"2024-11-25 23:40","pubTimestamp":1732549200,"startTime":"0","endTime":"0","summary":"Halozyme Therapeutics, Inc. HALO announced that it has withdrawn its non-binding proposal to acquire Evotec SE EVO for 11.00 per share in cash. The acquisition offer implied a fully diluted equity value of 2.0 billion.Halozyme decided to withdraw the acquisition bid following the unwillingness of Evotec’s management to discuss the potential buyout offer. EVO maintained its desire to remain an independent company.Besides withdrawing the buyout offer, HALO also reaffirmed its 2024 revenue guidance that was provided last month.Shares of Halozyme were up 7.2% on Nov. 22 following the announcement of the news. The stock has rallied 32.6% so far this year against the industry’s decline of 8.5%.Earlier this month, Halozyme submitted its non-binding proposal to acquire Evotec for 11.00 per share in cash. The offer represented a premium of 109% to EVO's undisturbed share price on Oct. 15, 2024.The acquisition would have diversified HALO’s business operation and also likely extended Halozyme’s r","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cYhdSHZ3kDYVQNhcMTsM_w--~B/aD0zOTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4a0e141116a5c1fff5e57140486a1890","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cYhdSHZ3kDYVQNhcMTsM_w--~B/aD0zOTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4a0e141116a5c1fff5e57140486a1890"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/halo-withdraws-acquisition-bid-evo-154000431.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPRO","EVO","CSTL","BK4196","LU0053671581.USD","BK4121","BK4139","HALO"],"gpt_icon":0},{"id":"2485129286","title":"Corcept Shares Rise More Than 60% in Three Months: Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2485129286","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485129286?lang=en_us&edition=fundamental","pubTime":"2024-11-23 00:32","pubTimestamp":1732293120,"startTime":"0","endTime":"0","summary":"Shares of Corcept Therapeutics Incorporated CORT have rallied 60.7% in the past three months against the industry’s decline of 9.9%.The company’s sole-marketed drug, Korlym , which is approved for treating Cushing's syndrome, has been performing well. The drug has been witnessing a strong demand in the past couple of quarters and the trend is likely to continue in 2025.The company is also making good progress with its promising set of pipeline candidates.Factors Driving CORT Stock in the Given Time Frame. Corcept’s top line solely comprises product sales from Korlym. The drug has been a consistent revenue driver for the company since approval. Sales of the drug increased 42.1% year over year to $493.2 million in the first nine months of 2024, owing to the strong demand and a record number of patients receiving the medication.Owing to the strong performance, CORT increased its annual revenue guidance for Korlym concurrently with third-quarter results. The company now expects total reven","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.WQmSb1MJO1_eLnmBVS1zA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.WQmSb1MJO1_eLnmBVS1zA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/corcept-shares-rise-more-60-163200157.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1559883803.SGD","IMCR","BK4532","CORT","LU0566484027.USD","BK4505","BK4007","BK4139","CSTL","BK4196","SPRO"],"gpt_icon":0},{"id":"2485144543","title":"JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2485144543","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485144543?lang=en_us&edition=fundamental","pubTime":"2024-11-22 01:08","pubTimestamp":1732208880,"startTime":"0","endTime":"0","summary":"Jazz Pharmaceuticals JAZZ announced that the FDA has granted accelerated approval to its intravenously administered drug zanidatamab for certain patients with biliary tract cancer . The drug will be marketed under the trade name Ziihera.With this nod, Ziihera gets approved for use in previously treated adult patients with unresectable or metastatic HER2-positive BTC. The approval also makes this drug the first dual HER2-targeted bispecific antibody and chemotherapy-free therapy for treating BTC in the country.The commercial launch of the drug is expected before this year’s end.The FDA’s approval is based on data from the phase IIb HERIZON-BTC-01 study on zanidatamab in the above indication. The study achieved its primary endpoint — patients who were treated with the drug achieved an objective response rate of 52%, with a median duration of response of 14.9 months.In the past 60 days, estimates for CytomX Therapeutics’ 2024 loss per share have narrowed from 29 cents to 13 cents. Estimat","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jazz-secures-fda-approval-ziihera-170800441.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["JAZZ","BK4196","BK4007","BK4532","CSTL","SPRO","LU0109394709.USD","LU0889565916.HKD","BTC","LU0320765992.SGD","BK4139","BK4533","CTMX"],"gpt_icon":0},{"id":"2485341065","title":"PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2485341065","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485341065?lang=en_us&edition=fundamental","pubTime":"2024-11-22 00:11","pubTimestamp":1732205460,"startTime":"0","endTime":"0","summary":"Puma Biotechnology, Inc. PBYI announced that it has initiated the phase II ALISCA-Breast1 study evaluating its pipeline candidate, alisertib, for the treatment of patients with metastatic breast cancer.The ALISCA-Breast1 study is investigating alisertib in combination with endocrine therapy for treating hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative  recurrent or metastatic breast cancer in patients who have been previously treated with CDK 4/6 inhibitors and have received at least two prior lines of endocrine therapy in the recurrent or metastatic setting.The main objective of the ALISCA-Breast1 study is to determine the optimal dose of alisertib in combination with a selected endocrine therapy. Initial data from the study is expected in 2025.Upon finding the optimal dose of alisertib, PBYI plans to meet with global regulatory agencies for the design of a pivotal phase III study on the candidate. The study will evaluate alisertib plus investigator’s","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pbyi-begins-phase-ii-study-161100190.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4196","SPRO","BK4139","IMCR","CSTL","BK4505","PBYI"],"gpt_icon":0},{"id":"2485410617","title":"SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2485410617","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485410617?lang=en_us&edition=fundamental","pubTime":"2024-11-21 23:56","pubTimestamp":1732204560,"startTime":"0","endTime":"0","summary":"Sage Therapeutics’ SAGE phase II study evaluating its neuropsychiatric candidate, dalzanemdor , for treating cognitive impairment  associated with Huntington’s Disease  failed to meet the primary endpoint.The double-blind, placebo-controlled DIMENSION study evaluated the effects of dalzanemdor in participants with CI associated with HD.Top-line data from the study showed that dalzanemdor failed to demonstrate a statistically significant difference from baseline compared to placebo on the Symbol Digit Modalities Test, a measure of cognitive function, at day 84. This was the primary endpoint of the study.The stock hit its 52-week low on the pipeline setback. Year to date, shares of Sage Therapeutics have plunged 77.3% compared with the industry’s decline of 8.5%.An inherited disorder, HD, causes nerve cells  in brain parts to gradually break down and die. CI is one of the most under-recognized aspects of HD. Currently, no treatment options are available to improve HD-related cognitive ef","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sages-dalzanemdor-fails-meet-goal-155600924.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","LU0823434740.USD","LU1093756325.SGD","SG9999001440.SGD","IE00BSNM7G36.USD","LU0689472784.USD","LU1162221912.USD","BK4083","LU2756315318.SGD","BK4139","BK4581","LU0058720904.USD","SPRO","BK4533","LU0943347566.SGD","CSTL","LU0820561909.HKD","LU1169589451.USD","MCI","BK4504","LU1674673428.USD","LU1169590202.USD","HD","LU0234572021.USD","BK4023","IE00B19Z3B42.SGD","IE00BWXC8680.SGD","IMCR","BK4566","LU0823434583.USD","LU0942090050.USD","LU1035775433.USD","BK4196","BK4567","LU1551013342.USD","LU0354030511.USD","LU2756315664.SGD","PD","LU1551013425.SGD","IE0002270589.USD","LU0823411888.USD","SAGE","BK4505","CI","LU0820562030.AUD","LU1778281490.HKD","BK4550","LU0079474960.USD","IE00B1XK9C88.USD","BK4588"],"gpt_icon":0},{"id":"2485149103","title":"Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485149103","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485149103?lang=en_us&edition=fundamental","pubTime":"2024-11-20 22:30","pubTimestamp":1732113000,"startTime":"0","endTime":"0","summary":"Shares of Grifols GRFS lost over 8% on Tuesday after the company’s board refused to endorse Canada-based Brookfield Asset Management’s offer to acquire its outstanding share capital for 6.45 billion .Per a regulatory filing submitted to the SEC, Grifols stated that the valuation offered by Brookfield “significantly undervalues the company’s fundamental prospects and its long-term potential.”Brookfield, along with key shareholders of Grifols, had expressed its intent for a potential takeover of the company in July. These key shareholders are the members of the Grifols family as well as founders of the company.Per a Bloomberg article, the Grifols family owns about a third of the company.In the past 60 days, estimates for CytomX Therapeutics’ 2024 loss per share have narrowed from 29 cents to 13 cents. Estimates for 2025 loss per share have narrowed","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/grifols-board-rejects-brookfields-buyout-143000792.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSTL","CTMX","SPRO","GRFS","BK4196","BAM","BK4139"],"gpt_icon":0},{"id":"2484903430","title":"FATE Presents Encourgaing Data From Lupus Study, Stock Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2484903430","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484903430?lang=en_us&edition=fundamental","pubTime":"2024-11-20 02:55","pubTimestamp":1732042500,"startTime":"0","endTime":"0","summary":"Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in its early-stage study on experimental pipeline candidate FT819.Data showed that the first patient suffering from active lupus nephritis  and treated with FT819 had favorable clinical experience, achieved drug-free clinical remission and continued on-study free of all immunosuppressive therapy.Shares of Fate have lost 42.8% year to date compared with the industry’s decline of 11.1%.FT819 is FATE’s off-the-shelf, CD19-targeted, 1XX CAR T-cell product candidate comprised of CD8αβ+ T cells with a memory phenotype and high CXCR4 expression to promote tissue trafficking.The initial results are promising, and FATE believes this differentiated therapeutic approach has the potential to transform outcomes for patients with autoimmune diseases without requiring patient apheresis, discontinuation of maintenance therapy, intense conditioning chemotherapy and extended hospital","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/j1FS0yeEY913fehDKxmAwA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/56d1b0639f9b169b5b1e773c99d1da8d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/j1FS0yeEY913fehDKxmAwA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/56d1b0639f9b169b5b1e773c99d1da8d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fate-presents-encourgaing-data-lupus-185500828.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SLE","BK4505","BK4139","BK4196","IMCR","CSTL","FATE","BK4077","SPRO"],"gpt_icon":0},{"id":"2484928765","title":"CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2484928765","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484928765?lang=en_us&edition=fundamental","pubTime":"2024-11-19 21:23","pubTimestamp":1732022580,"startTime":"0","endTime":"0","summary":"AstraZeneca AZN announced that the EMA’s Committee for Medicinal Products for Human Use  recommended approving its blockbuster cancer drug Tagrisso for expanded use across a new setting in the non-small cell lung cancer  setting.The CHMP has recommended approving Tagrisso for treating adult patients with locally advanced, unresectable NSCLC with EGFR exon 19 deletions  or exon 21 L858R substitution  mutations, whose disease has not progressed during or following platinum-based chemoradiation therapy. The FDA approved this combination in September for a similar indication.This recommendation is based on data from the phase III LAURAstudy, which showed that treatment with Tagrisso reduced the risk of disease progression or death by 84% versus placebo. Patients treated with the drug experienced a median progression-free survival of 39.1 months compared with 5.6 months for patients in the placebo group.Tagrisso is currently approved in the EU for four indications, all across different sett","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/6pmiwRZRhtc7hxDNA3zxVQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ef77d5a5eb4e72e4dd31ccfaf4ca4ccd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/6pmiwRZRhtc7hxDNA3zxVQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ef77d5a5eb4e72e4dd31ccfaf4ca4ccd"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chmp-endorses-astrazenecas-tagrisso-expanded-132300129.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4196","BK4585","BK4007","CHMP","LU2456880835.USD","LU2236285917.USD","LU1829250122.USD","CSTL","BK4139","LU0320765992.SGD","BK4588","SPRO","BK4568","CTMX","LU2462157665.USD","LU0109394709.USD","BK4087","LU2417539215.USD","LU0889565916.HKD","AZN"],"gpt_icon":0},{"id":"2484167368","title":"Spero Therapeutics Cut to Hold From Buy by TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2484167368","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484167368?lang=en_us&edition=fundamental","pubTime":"2024-11-18 22:10","pubTimestamp":1731939000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SPRO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 18, 2024 09:10 ET (14:10 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TD","BK4566","BK4127","COWN","LENZ","BK4207","BK4585","SPRO","BK4139"],"gpt_icon":0},{"id":"2484567937","title":"CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2484567937","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484567937?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:42","pubTimestamp":1731933720,"startTime":"0","endTime":"0","summary":"The CHMP has recommended the Rybrevant-Lazcluze combination as a first-line treatment for adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions  or exon 21 L858R substitution  mutations. The FDA approved this combination in August for a similar indication.This recommendation is based on data from the phase III MARIPOSA study, which evaluated the Rybrevant-Lazcluze combo against AstraZeneca’s AZN blockbuster oncology drug Tagrisso in patients with the above indication.Data from the MARIPOSA study showed that treatment with the JNJ combination therapy reduced the risk of disease progression or death by 30% compared withAZN’s Tagrisso. Patients who took the combo achieved a median duration of response  that was nine months longer than those treated with the AstraZeneca drug.Year to date, J&J’s shares have moved down 1.8% against the industry’s 3.3% growth.J&J currently carries a Zacks Rank #3 .","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/oeK5rO4fDl1d34mN96F56A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f3f15a36f635cd8200884e1a968d4c3d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/oeK5rO4fDl1d34mN96F56A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f3f15a36f635cd8200884e1a968d4c3d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chmp-endorses-j-js-rybrevant-124200522.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","IE00B42XCP33.USD","LU1244550494.USD","LU1023059063.AUD","LU1894683264.USD","LU0912757837.SGD","IE00B1BXHZ80.USD","LU1829250122.USD","BK4139","LU0795875086.SGD","LU1066051811.HKD","LU1929549753.HKD","IE00BJJMRZ35.SGD","SPRO","IE00B19Z3581.USD","BK4533","LU1261432733.SGD","CSTL","LU1585245621.USD","LU1066053197.SGD","LU1066051225.USD","JNJ","LU1244550577.SGD","LU2347655156.SGD","LU0234570918.USD","LU0345769631.USD","IE00BGHQF631.EUR","BK4196","BK4592","AZN","LU1732799900.SGD","BK4568","LU1032955483.USD","LU1074936037.SGD","IE000M9KFDE8.USD","LU1506573853.SGD","IE00B4R5TH58.HKD","LU0345770308.USD","IE0002141913.USD","LU1057294990.SGD","IE0002270589.USD","LU0466842654.USD","IE00BDGV0183.EUR","LU1935042991.SGD","LU1244550221.USD","BK4087","LU0203345920.USD","SG9999002232.USD","CHMP","LU0098860793.USD"],"gpt_icon":0},{"id":"2484693507","title":"TD Cowen downgrades Spero Therapeutics (SPRO) to a Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2484693507","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484693507?lang=en_us&edition=fundamental","pubTime":"2024-11-18 11:15","pubTimestamp":1731899723,"startTime":"0","endTime":"0","summary":"Spero Therapeutics (SPRO – Research Report) received a Hold rating and price target from TD Cowen analyst Ritu Baral yesterday. The company’s share...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-downgrades-spero-therapeutics-spro-to-a-hold?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-downgrades-spero-therapeutics-spro-to-a-hold?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COWN","SPRO","TD"],"gpt_icon":0},{"id":"2483649365","title":"Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2483649365","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483649365?lang=en_us&edition=fundamental","pubTime":"2024-11-15 06:35","pubTimestamp":1731623702,"startTime":"0","endTime":"0","summary":"Spero Therapeutics, Inc.  came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to earnings of $0.02 per share a year ago. These figures are adjusted for non-recurring items.Spero Therapeutics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $13.47 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 41.44%. This compares to year-ago revenues of $25.47 million. The company has topped consensus revenue estimates two times over the last four quarters.Spero Therapeutics shares have lost about 10.9% since the beginning of the year versus the S&P 500's gain of 25.5%.While Spero Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. I","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/AwCmIhR0z9Bg4cEkwuNQjw--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/AwCmIhR0z9Bg4cEkwuNQjw--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spero-therapeutics-inc-spro-reports-223502645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PHR","SPRO"],"gpt_icon":0},{"id":"2483337326","title":"BRIEF-Spero Therapeutics Q3 EPS USD -0.32","url":"https://stock-news.laohu8.com/highlight/detail?id=2483337326","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483337326?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:05","pubTimestamp":1731618346,"startTime":"0","endTime":"0","summary":"BRIEF-Spero Therapeutics Q3 EPS USD -0.32\n\n\nNov 14 (Reuters) - Spero Therapeutics Q3 operating expenses USD 32.062 million.\n\nQ3 income from operation USD -18.593 million\nQ3 net income USD -17.437 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nPLX9F7B79:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRO"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":103,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SPRO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-27","symbol":"SPRO","fiscalQuarterEnding":"2024/12","expectedEps":-0.35,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"post","actualEps":-0.38},{"market":"US","date":"2024-11-14","symbol":"SPRO","fiscalQuarterEnding":"2024/09","expectedEps":-0.27,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-0.32},{"market":"US","date":"2024-08-05","symbol":"SPRO","fiscalQuarterEnding":"2024/06","expectedEps":-0.35,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1722830400000,"reportTimeType":"post","actualEps":-0.33},{"market":"US","date":"2024-05-15","symbol":"SPRO","fiscalQuarterEnding":"2024/03","expectedEps":-0.07,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":-0.24},{"market":"US","date":"2024-03-13","symbol":"SPRO","fiscalQuarterEnding":"2023/12","expectedEps":-0.18,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1710302400000,"reportTimeType":"post","actualEps":0.96}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SPRO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SPRO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.3333,"hold":0.6667,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.6667,"analysts":3,"updateTime":1743220800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SPRO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SPRO","date":"2025-04-17","current":-0.603309,"percent":0.711601,"low":-57.13681,"twenty":-5.995124,"median":-3.113595,"eighty":-0.223574,"high":18.622772,"avg":-4.181344,"sd":12.508619,"marketCap":41366474},"quantilePoints":[{"date":"2020-04-24","current":-2.869491,"twenty":-5.287923,"median":-4.591235,"eighty":-3.725456,"marketCap":174823724},{"date":"2020-05-01","current":-4.000604,"twenty":-5.286529,"median":-4.581276,"eighty":-3.724053,"marketCap":243736796},{"date":"2020-05-08","current":-3.066735,"twenty":-5.280556,"median":-4.577339,"eighty":-3.724053,"marketCap":242612492},{"date":"2020-05-15","current":-3.105785,"twenty":-5.277465,"median":-4.571125,"eighty":-3.716642,"marketCap":245701785},{"date":"2020-05-22","current":-3.254176,"twenty":-5.271167,"median":-4.561447,"eighty":-3.701399,"marketCap":257441100},{"date":"2020-05-29","current":-3.077149,"twenty":-5.270013,"median":-4.557451,"eighty":-3.646094,"marketCap":243436304},{"date":"2020-06-05","current":-3.238556,"twenty":-5.266561,"median":-4.548464,"eighty":-3.57866,"marketCap":256205382},{"date":"2020-06-12","current":-3.110992,"twenty":-5.261058,"median":-4.534867,"eighty":-3.515876,"marketCap":246113691},{"date":"2020-06-19","current":-3.49108,"twenty":-5.2489,"median":-4.521243,"eighty":-3.49605,"marketCap":276182812},{"date":"2020-06-26","current":-3.425996,"twenty":-5.2489,"median":-4.5202,"eighty":-3.49605,"marketCap":271033990},{"date":"2020-07-02","current":-3.480666,"twenty":-5.240349,"median":-4.516506,"eighty":-3.490924,"marketCap":275359000},{"date":"2020-07-10","current":-3.389549,"twenty":-5.234972,"median":-4.511552,"eighty":-3.490924,"marketCap":268150649},{"date":"2020-07-17","current":-3.474158,"twenty":-5.230001,"median":-4.500168,"eighty":-3.486914,"marketCap":274844118},{"date":"2020-07-24","current":-3.155249,"twenty":-5.217365,"median":-4.491412,"eighty":-3.464005,"marketCap":249614890},{"date":"2020-07-31","current":-3.045909,"twenty":-5.214099,"median":-4.491045,"eighty":-3.447404,"marketCap":240964869},{"date":"2020-08-07","current":-3.289641,"twenty":-5.214007,"median":-4.488361,"eighty":-3.432244,"marketCap":274559982},{"date":"2020-08-14","current":-3.165455,"twenty":-5.210575,"median":-4.476068,"eighty":-3.42079,"marketCap":264195237},{"date":"2020-08-21","current":-3.259228,"twenty":-5.197198,"median":-4.468542,"eighty":-3.398692,"marketCap":272021677},{"date":"2020-08-28","current":-2.663646,"twenty":-5.190349,"median":-4.463316,"eighty":-3.384207,"marketCap":222313205},{"date":"2020-09-04","current":-2.270815,"twenty":-5.189419,"median":-4.454324,"eighty":-3.354954,"marketCap":189526767},{"date":"2020-09-11","current":-3.079737,"twenty":-5.189419,"median":-4.450031,"eighty":-3.345397,"marketCap":257041031},{"date":"2020-09-18","current":-3.141891,"twenty":-5.187231,"median":-4.443879,"eighty":-3.334445,"marketCap":262228539},{"date":"2020-09-25","current":-2.961644,"twenty":-5.183042,"median":-4.402047,"eighty":-3.315755,"marketCap":247184765},{"date":"2020-10-02","current":-3.7526,"twenty":-5.18104,"median":-4.397324,"eighty":-3.31211,"marketCap":313199466},{"date":"2020-10-09","current":-4.141551,"twenty":-5.179836,"median":-4.391541,"eighty":-3.315755,"marketCap":345662097},{"date":"2020-10-16","current":-4.045091,"twenty":-5.177529,"median":-4.357098,"eighty":-3.321863,"marketCap":337611365},{"date":"2020-10-23","current":-4.362475,"twenty":-5.176226,"median":-4.355698,"eighty":-3.325533,"marketCap":364100872},{"date":"2020-10-30","current":-4.079318,"twenty":-5.176016,"median":-4.345999,"eighty":-3.329863,"marketCap":340468076},{"date":"2020-11-06","current":-4.39207,"twenty":-5.1733,"median":-4.347495,"eighty":-3.334445,"marketCap":371924849},{"date":"2020-11-13","current":-4.597547,"twenty":-5.17009,"median":-4.357098,"eighty":-3.338553,"marketCap":389324842},{"date":"2020-11-20","current":-4.873656,"twenty":-5.166153,"median":-4.365586,"eighty":-3.343307,"marketCap":412706083},{"date":"2020-11-27","current":-5.371296,"twenty":-5.16715,"median":-4.391541,"eighty":-3.345335,"marketCap":454846690},{"date":"2020-12-04","current":-5.602457,"twenty":-5.176309,"median":-4.395779,"eighty":-3.345397,"marketCap":474421683},{"date":"2020-12-11","current":-5.522193,"twenty":-5.183953,"median":-4.40059,"eighty":-3.346453,"marketCap":467624810},{"date":"2020-12-18","current":-5.682722,"twenty":-5.192208,"median":-4.4074,"eighty":-3.350803,"marketCap":481218555},{"date":"2020-12-24","current":-7.053638,"twenty":-5.214007,"median":-4.442633,"eighty":-3.354954,"marketCap":597309133},{"date":"2020-12-31","current":-6.225309,"twenty":-5.234162,"median":-4.446594,"eighty":-3.354954,"marketCap":527165411},{"date":"2021-01-08","current":-5.368085,"twenty":-5.261058,"median":-4.450379,"eighty":-3.366119,"marketCap":454574816},{"date":"2021-01-15","current":-5.2814,"twenty":-5.270013,"median":-4.459539,"eighty":-3.373929,"marketCap":447234194},{"date":"2021-01-22","current":-6.032675,"twenty":-5.279365,"median":-4.463316,"eighty":-3.381717,"marketCap":510852918},{"date":"2021-01-29","current":-5.814355,"twenty":-5.288101,"median":-4.468542,"eighty":-3.384207,"marketCap":492365425},{"date":"2021-02-05","current":-6.411523,"twenty":-5.305613,"median":-4.476068,"eighty":-3.385101,"marketCap":542934155},{"date":"2021-02-12","current":-6.533525,"twenty":-5.332316,"median":-4.488361,"eighty":-3.38727,"marketCap":553265401},{"date":"2021-02-19","current":-6.594526,"twenty":-5.345052,"median":-4.491045,"eighty":-3.388835,"marketCap":558431024},{"date":"2021-02-26","current":-5.833619,"twenty":-5.361227,"median":-4.491318,"eighty":-3.396406,"marketCap":493996675},{"date":"2021-03-05","current":-5.246083,"twenty":-5.368258,"median":-4.500168,"eighty":-3.402401,"marketCap":444243570},{"date":"2021-03-12","current":-6.309418,"twenty":-5.371976,"median":-4.50969,"eighty":-3.412251,"marketCap":493901262},{"date":"2021-03-19","current":-5.981509,"twenty":-5.387929,"median":-4.516354,"eighty":-3.419748,"marketCap":468232558},{"date":"2021-03-26","current":-5.205082,"twenty":-5.390332,"median":-4.5202,"eighty":-3.42079,"marketCap":407453789},{"date":"2021-04-01","current":-5.382228,"twenty":-5.390408,"median":-4.521243,"eighty":-3.420837,"marketCap":421320789},{"date":"2021-04-09","current":-4.92994,"twenty":-5.390015,"median":-4.533574,"eighty":-3.422527,"marketCap":385915681},{"date":"2021-04-16","current":-4.873404,"twenty":-5.388431,"median":-4.546657,"eighty":-3.425372,"marketCap":381490043},{"date":"2021-04-23","current":-4.96763,"twenty":-5.385512,"median":-4.556667,"eighty":-3.42912,"marketCap":388866107},{"date":"2021-04-30","current":-5.186236,"twenty":-5.384138,"median":-4.561447,"eighty":-3.434848,"marketCap":405978576},{"date":"2021-05-07","current":-5.34766,"twenty":-5.383374,"median":-4.571125,"eighty":-3.437796,"marketCap":398106514},{"date":"2021-05-14","current":-5.550887,"twenty":-5.383374,"median":-4.577339,"eighty":-3.443639,"marketCap":413235748},{"date":"2021-05-21","current":-5.778023,"twenty":-5.388431,"median":-4.581276,"eighty":-3.449286,"marketCap":430144892},{"date":"2021-05-28","current":-5.778023,"twenty":-5.40792,"median":-4.591235,"eighty":-3.449342,"marketCap":430144892},{"date":"2021-06-04","current":-5.662462,"twenty":-5.417705,"median":-4.597317,"eighty":-3.449426,"marketCap":421541994},{"date":"2021-06-11","current":-6.144628,"twenty":-5.434813,"median":-4.599337,"eighty":-3.453071,"marketCap":457436844},{"date":"2021-06-18","current":-5.845765,"twenty":-5.446368,"median":-4.604387,"eighty":-3.468018,"marketCap":435187970},{"date":"2021-06-25","current":-5.944218,"twenty":-5.457323,"median":-4.615778,"eighty":-3.470102,"marketCap":442517290},{"date":"2021-07-02","current":-6.299275,"twenty":-5.46757,"median":-4.61859,"eighty":-3.472876,"marketCap":468949531},{"date":"2021-07-09","current":-6.287307,"twenty":-5.475294,"median":-4.622569,"eighty":-3.474158,"marketCap":468058556},{"date":"2021-07-16","current":-5.756716,"twenty":-5.489092,"median":-4.626391,"eighty":-3.480666,"marketCap":428558691},{"date":"2021-07-23","current":-5.716821,"twenty":-5.500087,"median":-4.638695,"eighty":-3.480666,"marketCap":425588776},{"date":"2021-07-30","current":-5.32187,"twenty":-5.502843,"median":-4.646898,"eighty":-3.488476,"marketCap":396186620},{"date":"2021-08-06","current":-6.019339,"twenty":-5.513362,"median":-4.65834,"eighty":-3.4903,"marketCap":454556416},{"date":"2021-08-13","current":-5.755408,"twenty":-5.525665,"median":-4.663304,"eighty":-3.4903,"marketCap":434625371},{"date":"2021-08-20","current":-6.581258,"twenty":-5.533309,"median":-4.666253,"eighty":-3.49108,"marketCap":496990254},{"date":"2021-08-27","current":-7.219801,"twenty":-5.546817,"median":-4.67971,"eighty":-3.494402,"marketCap":545210525},{"date":"2021-09-03","current":-7.624212,"twenty":-5.552096,"median":-4.686116,"eighty":-3.49605,"marketCap":575750029},{"date":"2021-09-10","current":-7.798748,"twenty":-5.562419,"median":-4.693364,"eighty":-3.499653,"marketCap":588930237},{"date":"2021-09-17","current":-8.152075,"twenty":-5.582179,"median":-4.697982,"eighty":-3.503388,"marketCap":615612120},{"date":"2021-09-24","current":-7.973283,"twenty":-5.594764,"median":-4.710228,"eighty":-3.509466,"marketCap":602110444},{"date":"2021-10-01","current":-7.470962,"twenty":-5.603316,"median":-4.715815,"eighty":-3.514862,"marketCap":564177164},{"date":"2021-10-08","current":-7.270885,"twenty":-5.619957,"median":-4.72441,"eighty":-3.518383,"marketCap":549068146},{"date":"2021-10-15","current":-7.245343,"twenty":-5.64147,"median":-4.72918,"eighty":-3.521658,"marketCap":547139335},{"date":"2021-10-22","current":-7.177232,"twenty":-5.657325,"median":-4.732389,"eighty":-3.522954,"marketCap":541995840},{"date":"2021-10-29","current":-7.475219,"twenty":-5.670933,"median":-4.736196,"eighty":-3.536236,"marketCap":564498633},{"date":"2021-11-05","current":-7.458191,"twenty":-5.687453,"median":-4.740792,"eighty":-3.542421,"marketCap":563212759},{"date":"2021-11-12","current":-6.86102,"twenty":-5.711236,"median":-4.749034,"eighty":-3.563973,"marketCap":542713529},{"date":"2021-11-19","current":-6.742515,"twenty":-5.718593,"median":-4.751989,"eighty":-3.576764,"marketCap":533339680},{"date":"2021-11-26","current":-6.174509,"twenty":-5.742633,"median":-4.762697,"eighty":-3.582625,"marketCap":488409852},{"date":"2021-12-03","current":-5.541121,"twenty":-5.745538,"median":-4.767707,"eighty":-3.588112,"marketCap":438308246},{"date":"2021-12-10","current":-5.569726,"twenty":-5.747863,"median":-4.770134,"eighty":-3.591569,"marketCap":440570899},{"date":"2021-12-17","current":-5.553381,"twenty":-5.745538,"median":-4.78812,"eighty":-3.601982,"marketCap":439277955},{"date":"2021-12-23","current":-5.729095,"twenty":-5.744668,"median":-4.791373,"eighty":-3.610941,"marketCap":453177110},{"date":"2021-12-31","current":-6.542283,"twenty":-5.752225,"median":-4.794534,"eighty":-3.616718,"marketCap":517501108},{"date":"2022-01-07","current":-5.353148,"twenty":-5.753772,"median":-4.807458,"eighty":-3.62158,"marketCap":423439382},{"date":"2022-01-14","current":-5.394012,"twenty":-5.752225,"median":-4.812969,"eighty":-3.626637,"marketCap":426671744},{"date":"2022-01-21","current":-4.740192,"twenty":-5.749384,"median":-4.815545,"eighty":-3.632464,"marketCap":374953957},{"date":"2022-01-28","current":-4.531787,"twenty":-5.746075,"median":-4.808831,"eighty":-3.647672,"marketCap":358468912},{"date":"2022-02-04","current":-4.343814,"twenty":-5.744835,"median":-4.802417,"eighty":-3.65681,"marketCap":343600048},{"date":"2022-02-11","current":-4.106805,"twenty":-5.743655,"median":-4.792518,"eighty":-3.669066,"marketCap":324852350},{"date":"2022-02-18","current":-3.783981,"twenty":-5.74156,"median":-4.791069,"eighty":-3.673506,"marketCap":299316693},{"date":"2022-02-25","current":-3.873881,"twenty":-5.741354,"median":-4.78527,"eighty":-3.672903,"marketCap":306427889},{"date":"2022-03-04","current":-3.518367,"twenty":-5.741354,"median":-4.7699,"eighty":-3.669563,"marketCap":278306342},{"date":"2022-03-11","current":-3.416208,"twenty":-5.737401,"median":-4.767881,"eighty":-3.646094,"marketCap":270225438},{"date":"2022-03-18","current":-3.42438,"twenty":-5.729095,"median":-4.765727,"eighty":-3.615008,"marketCap":270871910},{"date":"2022-03-25","current":-3.330394,"twenty":-5.720811,"median":-4.751989,"eighty":-3.585269,"marketCap":263437478},{"date":"2022-04-01","current":-2.594724,"twenty":-5.718038,"median":-4.749034,"eighty":-3.543147,"marketCap":232892024},{"date":"2022-04-08","current":-2.685959,"twenty":-5.716835,"median":-4.743166,"eighty":-3.523112,"marketCap":241080914},{"date":"2022-04-14","current":-2.229784,"twenty":-5.716824,"median":-4.739876,"eighty":-3.518367,"marketCap":200136465},{"date":"2022-04-22","current":-1.999871,"twenty":-5.713858,"median":-4.736196,"eighty":-3.503388,"marketCap":179500463},{"date":"2022-04-29","current":-1.773609,"twenty":-5.712894,"median":-4.732389,"eighty":-3.490924,"marketCap":159192016},{"date":"2022-05-06","current":-0.755426,"twenty":-5.711236,"median":-4.72918,"eighty":-3.48159,"marketCap":67804007},{"date":"2022-05-13","current":-0.624047,"twenty":-5.702858,"median":-4.72441,"eighty":-3.473837,"marketCap":56012005},{"date":"2022-05-20","current":-0.439054,"twenty":-5.700864,"median":-4.715815,"eighty":-3.449426,"marketCap":45293730},{"date":"2022-05-27","current":-0.394513,"twenty":-5.699193,"median":-4.710228,"eighty":-3.447094,"marketCap":40698714},{"date":"2022-06-03","current":-0.330882,"twenty":-5.690284,"median":-4.702589,"eighty":-3.433305,"marketCap":34134405},{"date":"2022-06-10","current":-0.340426,"twenty":-5.683482,"median":-4.696894,"eighty":-3.422991,"marketCap":35119052},{"date":"2022-06-17","current":-0.298366,"twenty":-5.682255,"median":-4.689296,"eighty":-3.417395,"marketCap":30780043},{"date":"2022-06-24","current":-0.299066,"twenty":-5.678341,"median":-4.684128,"eighty":-3.397857,"marketCap":30852251},{"date":"2022-07-01","current":-0.263242,"twenty":-5.671936,"median":-4.673321,"eighty":-3.386215,"marketCap":27156545},{"date":"2022-07-08","current":-0.262351,"twenty":-5.670421,"median":-4.665101,"eighty":-3.380277,"marketCap":27064645},{"date":"2022-07-15","current":-0.251343,"twenty":-5.668792,"median":-4.662662,"eighty":-3.355763,"marketCap":25929019},{"date":"2022-07-22","current":-0.239603,"twenty":-5.661665,"median":-4.658465,"eighty":-3.345397,"marketCap":24717904},{"date":"2022-07-29","current":-0.232953,"twenty":-5.658189,"median":-4.649834,"eighty":-3.332999,"marketCap":24031934},{"date":"2022-08-05","current":-0.271941,"twenty":-5.656983,"median":-4.638695,"eighty":-3.324822,"marketCap":28053981},{"date":"2022-08-12","current":-0.241477,"twenty":-5.656009,"median":-4.630492,"eighty":-3.298983,"marketCap":27352632},{"date":"2022-08-19","current":-0.304169,"twenty":-5.651859,"median":-4.622849,"eighty":-3.28605,"marketCap":34453796},{"date":"2022-08-26","current":-0.28064,"twenty":-5.646896,"median":-4.61859,"eighty":-3.259567,"marketCap":31788667},{"date":"2022-09-02","current":-0.224976,"twenty":-5.644127,"median":-4.615778,"eighty":-3.246458,"marketCap":25483535},{"date":"2022-09-09","current":-0.346737,"twenty":-5.640585,"median":-4.6058,"eighty":-3.222936,"marketCap":39275574},{"date":"2022-09-16","current":-0.278628,"twenty":-5.637707,"median":-4.599337,"eighty":-3.215126,"marketCap":31560729},{"date":"2022-09-23","current":-0.609885,"twenty":-5.631352,"median":-4.597547,"eighty":-3.190148,"marketCap":69082929},{"date":"2022-09-30","current":-0.619173,"twenty":-5.622753,"median":-4.591235,"eighty":-3.174978,"marketCap":70134954},{"date":"2022-10-07","current":-0.578927,"twenty":-5.619258,"median":-4.581276,"eighty":-3.159693,"marketCap":65576181},{"date":"2022-10-14","current":-0.612981,"twenty":-5.617086,"median":-4.577339,"eighty":-3.153712,"marketCap":69433604},{"date":"2022-10-21","current":-0.585118,"twenty":-5.607799,"median":-4.571125,"eighty":-3.144373,"marketCap":66277531},{"date":"2022-10-28","current":-0.609885,"twenty":-5.605826,"median":-4.563951,"eighty":-3.129215,"marketCap":69082929},{"date":"2022-11-04","current":-0.585118,"twenty":-5.602689,"median":-4.558235,"eighty":-3.117302,"marketCap":66277531},{"date":"2022-11-11","current":-0.750715,"twenty":-5.602457,"median":-4.550515,"eighty":-3.107707,"marketCap":85034954},{"date":"2022-11-18","current":-0.94528,"twenty":-5.602457,"median":-4.53616,"eighty":-3.104599,"marketCap":96821219},{"date":"2022-11-25","current":-0.970555,"twenty":-5.599889,"median":-4.531787,"eighty":-3.094731,"marketCap":99410021},{"date":"2022-12-02","current":-0.970555,"twenty":-5.598514,"median":-4.521243,"eighty":-3.082423,"marketCap":99410021},{"date":"2022-12-09","current":-0.88462,"twenty":-5.594581,"median":-4.519318,"eighty":-3.068818,"marketCap":90608092},{"date":"2022-12-16","current":-0.849235,"twenty":-5.593249,"median":-4.516004,"eighty":-3.045488,"marketCap":86983769},{"date":"2022-12-23","current":-0.80374,"twenty":-5.590343,"median":-4.507828,"eighty":-3.001981,"marketCap":82323924},{"date":"2022-12-30","current":-0.87451,"twenty":-5.587699,"median":-4.500168,"eighty":-2.925595,"marketCap":89572571},{"date":"2023-01-06","current":-0.909895,"twenty":-5.587699,"median":-4.491045,"eighty":-2.881897,"marketCap":93196895},{"date":"2023-01-13","current":-1.010994,"twenty":-5.587699,"median":-4.477497,"eighty":-2.7929,"marketCap":103552106},{"date":"2023-01-20","current":-0.950335,"twenty":-5.587699,"median":-4.466436,"eighty":-2.732909,"marketCap":97338979},{"date":"2023-01-27","current":-0.920005,"twenty":-5.587699,"median":-4.454324,"eighty":-2.67399,"marketCap":94232416},{"date":"2023-02-03","current":-0.960445,"twenty":-5.583235,"median":-4.443439,"eighty":-2.641266,"marketCap":98374500},{"date":"2023-02-10","current":-0.90484,"twenty":-5.583235,"median":-4.402047,"eighty":-2.609436,"marketCap":92679134},{"date":"2023-02-17","current":-0.8644,"twenty":-5.583235,"median":-4.39207,"eighty":-2.581469,"marketCap":88537050},{"date":"2023-02-24","current":-0.763301,"twenty":-5.583235,"median":-4.365586,"eighty":-2.554574,"marketCap":78181840},{"date":"2023-03-03","current":-0.753191,"twenty":-5.583235,"median":-4.351987,"eighty":-2.49002,"marketCap":77146318},{"date":"2023-03-10","current":-0.748136,"twenty":-5.583235,"median":-4.340393,"eighty":-2.435794,"marketCap":76628558},{"date":"2023-03-17","current":-0.687476,"twenty":-5.569418,"median":-4.315732,"eighty":-2.391745,"marketCap":70415432},{"date":"2023-03-24","current":-0.722861,"twenty":-5.553381,"median":-4.306481,"eighty":-2.317441,"marketCap":74039755},{"date":"2023-03-31","current":-1.642338,"twenty":-5.547029,"median":-4.288241,"eighty":-2.269765,"marketCap":76229128},{"date":"2023-04-06","current":-1.642338,"twenty":-5.547029,"median":-4.263777,"eighty":-2.208281,"marketCap":76229128},{"date":"2023-04-14","current":-1.936826,"twenty":-5.538381,"median":-4.208866,"eighty":-2.122491,"marketCap":89897800},{"date":"2023-04-21","current":-1.902847,"twenty":-5.538381,"median":-4.199845,"eighty":-1.995117,"marketCap":88320645},{"date":"2023-04-28","current":-2.016112,"twenty":-5.538381,"median":-4.167033,"eighty":-1.97096,"marketCap":93577827},{"date":"2023-05-05","current":-2.129376,"twenty":-5.538381,"median":-4.134222,"eighty":-1.959479,"marketCap":98835008},{"date":"2023-05-12","current":-2.174682,"twenty":-5.538381,"median":-4.110891,"eighty":-1.959479,"marketCap":100937880},{"date":"2023-05-19","current":-3.524105,"twenty":-5.538381,"median":-4.110891,"eighty":-1.959479,"marketCap":94629263},{"date":"2023-05-26","current":-3.426213,"twenty":-5.538381,"median":-4.110891,"eighty":-1.959479,"marketCap":92000672},{"date":"2023-06-02","current":-3.524105,"twenty":-5.538381,"median":-4.110891,"eighty":-1.959479,"marketCap":94629263},{"date":"2023-06-09","current":-3.524105,"twenty":-5.538381,"median":-4.110891,"eighty":-1.959479,"marketCap":94629263},{"date":"2023-06-16","current":-3.073803,"twenty":-5.538381,"median":-4.110891,"eighty":-1.959479,"marketCap":82537746},{"date":"2023-06-23","current":-2.878019,"twenty":-5.538748,"median":-4.106805,"eighty":-1.959479,"marketCap":77280565},{"date":"2023-06-30","current":-2.780127,"twenty":-5.538932,"median":-4.088313,"eighty":-1.959479,"marketCap":74651974},{"date":"2023-07-07","current":-2.799705,"twenty":-5.535376,"median":-4.066769,"eighty":-1.959479,"marketCap":75177692},{"date":"2023-07-14","current":-2.975911,"twenty":-5.533309,"median":-4.057057,"eighty":-1.959479,"marketCap":79909155},{"date":"2023-07-21","current":-2.858441,"twenty":-5.533309,"median":-4.0428,"eighty":-1.959479,"marketCap":76754846},{"date":"2023-07-28","current":-2.721392,"twenty":-5.533309,"median":-4.025839,"eighty":-1.959479,"marketCap":73074820},{"date":"2023-08-04","current":-2.956332,"twenty":-5.533309,"median":-4.014818,"eighty":-1.959479,"marketCap":79383437},{"date":"2023-08-11","current":-7.559414,"twenty":-5.535376,"median":-4.006786,"eighty":-1.959479,"marketCap":76229128},{"date":"2023-08-18","current":-6.976353,"twenty":-5.547877,"median":-4.006786,"eighty":-1.959479,"marketCap":70349545},{"date":"2023-08-25","current":-6.796031,"twenty":-5.557245,"median":-4.006786,"eighty":-1.959479,"marketCap":68531175},{"date":"2023-09-01","current":-7.841574,"twenty":-5.577899,"median":-4.006786,"eighty":-1.959479,"marketCap":79074433},{"date":"2023-09-08","current":-7.00514,"twenty":-5.590343,"median":-4.006107,"eighty":-1.957214,"marketCap":70639827},{"date":"2023-09-15","current":-6.743754,"twenty":-5.600531,"median":-4.008698,"eighty":-1.954949,"marketCap":68004012},{"date":"2023-09-22","current":-6.377814,"twenty":-5.619353,"median":-4.008698,"eighty":-1.954949,"marketCap":64313872},{"date":"2023-09-27","current":-6.325536,"twenty":-5.635165,"median":-4.007465,"eighty":-1.952683,"marketCap":63786709},{"date":"2023-10-06","current":-6.064151,"twenty":-5.656766,"median":-4.006107,"eighty":-1.948153,"marketCap":61150895},{"date":"2023-10-13","current":-5.855042,"twenty":-5.670432,"median":-4.007465,"eighty":-1.948153,"marketCap":59042243},{"date":"2023-10-20","current":-5.724349,"twenty":-5.700864,"median":-4.017086,"eighty":-1.948153,"marketCap":57724336},{"date":"2023-10-27","current":-5.227716,"twenty":-5.700864,"median":-4.025257,"eighty":-1.940491,"marketCap":52716289},{"date":"2023-11-03","current":-5.959596,"twenty":-5.712838,"median":-4.040427,"eighty":-1.938575,"marketCap":60096569},{"date":"2023-11-10","current":-5.489102,"twenty":-5.718038,"median":-4.056342,"eighty":-1.938575,"marketCap":55352103},{"date":"2023-11-17","current":-38.091206,"twenty":-5.738192,"median":-4.064,"eighty":-1.938225,"marketCap":61479207},{"date":"2023-11-24","current":-39.076324,"twenty":-5.745362,"median":-4.0782,"eighty":-1.938225,"marketCap":63069187},{"date":"2023-12-01","current":-37.434462,"twenty":-5.756595,"median":-4.110221,"eighty":-1.938225,"marketCap":60419221},{"date":"2023-12-08","current":-41.374931,"twenty":-5.775828,"median":-4.143107,"eighty":-1.938575,"marketCap":66779139},{"date":"2023-12-15","current":-42.688421,"twenty":-5.801932,"median":-4.180228,"eighty":-1.938575,"marketCap":68899112},{"date":"2023-12-22","current":-44.658656,"twenty":-5.81944,"median":-4.20788,"eighty":-1.938575,"marketCap":72079071},{"date":"2023-12-29","current":-47.94238,"twenty":-5.826574,"median":-4.262087,"eighty":-1.938225,"marketCap":77379002},{"date":"2024-01-05","current":-48.270753,"twenty":-5.837472,"median":-4.288241,"eighty":-1.937875,"marketCap":77908995},{"date":"2024-01-12","current":-47.94238,"twenty":-5.855042,"median":-4.312399,"eighty":-1.937875,"marketCap":77379002},{"date":"2024-01-19","current":-46.300518,"twenty":-5.879021,"median":-4.328063,"eighty":-1.937526,"marketCap":74729036},{"date":"2024-01-26","current":-51.226105,"twenty":-5.88973,"median":-4.348245,"eighty":-1.937875,"marketCap":82678934},{"date":"2024-02-02","current":-51.554478,"twenty":-5.907523,"median":-4.3779,"eighty":-1.937875,"marketCap":83208927},{"date":"2024-02-09","current":-44.330283,"twenty":-5.93365,"median":-4.402487,"eighty":-1.937875,"marketCap":71549077},{"date":"2024-02-16","current":-49.912615,"twenty":-5.959596,"median":-4.448819,"eighty":-1.937875,"marketCap":80558961},{"date":"2024-02-23","current":-48.270753,"twenty":-5.960111,"median":-4.478613,"eighty":-1.937875,"marketCap":77908995},{"date":"2024-03-01","current":-54.181458,"twenty":-5.982254,"median":-4.491224,"eighty":-1.938225,"marketCap":87448873},{"date":"2024-03-08","current":-56.808437,"twenty":-6.011873,"median":-4.516354,"eighty":-1.938225,"marketCap":91688818},{"date":"2024-03-15","current":4.043621,"twenty":-6.022006,"median":-4.491224,"eighty":-1.934561,"marketCap":92218811},{"date":"2024-03-22","current":4.086364,"twenty":-6.022006,"median":-4.443439,"eighty":-1.853014,"marketCap":93193610},{"date":"2024-03-28","current":4.133605,"twenty":-6.022006,"median":-4.402047,"eighty":-1.811563,"marketCap":94270993},{"date":"2024-04-05","current":3.991881,"twenty":-6.024673,"median":-4.364031,"eighty":-1.717093,"marketCap":91038844},{"date":"2024-04-12","current":4.039122,"twenty":-6.024673,"median":-4.337431,"eighty":-1.389071,"marketCap":92116227},{"date":"2024-04-19","current":3.473759,"twenty":-6.024673,"median":-4.314454,"eighty":-0.978642,"marketCap":79222546},{"date":"2024-04-26","current":3.379235,"twenty":-6.022006,"median":-4.28696,"eighty":-0.969544,"marketCap":77066831},{"date":"2024-05-03","current":3.804593,"twenty":-6.022006,"median":-4.217087,"eighty":-0.959434,"marketCap":86767551},{"date":"2024-05-10","current":3.993641,"twenty":-6.022006,"median":-4.1681,"eighty":-0.950335,"marketCap":91078982},{"date":"2024-05-17","current":3.615427,"twenty":-6.011873,"median":-4.125993,"eighty":-0.940225,"marketCap":84611835},{"date":"2024-05-24","current":3.408173,"twenty":-6.011873,"median":-4.106805,"eighty":-0.93517,"marketCap":79761475},{"date":"2024-05-31","current":3.275692,"twenty":-6.011873,"median":-4.076207,"eighty":-0.930115,"marketCap":76661027},{"date":"2024-06-07","current":3.344897,"twenty":-6.011873,"median":-4.057326,"eighty":-0.924049,"marketCap":78280626},{"date":"2024-06-14","current":3.160351,"twenty":-6.011873,"median":-4.040427,"eighty":-0.90484,"marketCap":73961695},{"date":"2024-06-21","current":3.068078,"twenty":-6.003499,"median":-4.018913,"eighty":-0.896752,"marketCap":71802229},{"date":"2024-06-28","current":3.091146,"twenty":-5.980399,"median":-4.012297,"eighty":-0.878554,"marketCap":72342096},{"date":"2024-07-05","current":3.056544,"twenty":-5.980399,"median":-4.001489,"eighty":-0.868444,"marketCap":71532296},{"date":"2024-07-12","current":3.194953,"twenty":-5.980399,"median":-3.95478,"eighty":-0.853279,"marketCap":74771495},{"date":"2024-07-15","current":3.264158,"twenty":-5.980399,"median":-3.952342,"eighty":-0.847213,"marketCap":76391094},{"date":"2024-08-02","current":3.206488,"twenty":-5.989796,"median":-3.8984,"eighty":-0.814861,"marketCap":75041428},{"date":"2024-08-09","current":3.901571,"twenty":-5.989796,"median":-3.877968,"eighty":-0.80374,"marketCap":68101915},{"date":"2024-08-16","current":3.746746,"twenty":-5.989796,"median":-3.861795,"eighty":-0.763301,"marketCap":65399458},{"date":"2024-08-23","current":4.180254,"twenty":-5.989796,"median":-3.820123,"eighty":-0.75121,"marketCap":72966337},{"date":"2024-08-30","current":4.242184,"twenty":-5.989796,"median":-3.788068,"eighty":-0.744092,"marketCap":74047320},{"date":"2024-09-06","current":4.118324,"twenty":-5.989796,"median":-3.774547,"eighty":-0.731947,"marketCap":71885354},{"date":"2024-09-13","current":4.118324,"twenty":-5.989796,"median":-3.739031,"eighty":-0.708707,"marketCap":71885354},{"date":"2024-09-20","current":4.195737,"twenty":-5.989796,"median":-3.720328,"eighty":-0.687476,"marketCap":73236583},{"date":"2024-09-27","current":3.9635,"twenty":-5.989796,"median":-3.691537,"eighty":-0.654404,"marketCap":69182897},{"date":"2024-10-04","current":3.994465,"twenty":-5.989796,"median":-3.653986,"eighty":-0.635451,"marketCap":69723389},{"date":"2024-10-11","current":3.839641,"twenty":-5.989796,"median":-3.621997,"eighty":-0.621128,"marketCap":67020932},{"date":"2024-10-18","current":3.978983,"twenty":-5.989796,"median":-3.56918,"eighty":-0.619173,"marketCap":69453143},{"date":"2024-10-25","current":3.901571,"twenty":-5.989796,"median":-3.534712,"eighty":-0.609885,"marketCap":68101915},{"date":"2024-10-31","current":3.994465,"twenty":-5.989796,"median":-3.524105,"eighty":-0.607408,"marketCap":69723389},{"date":"2024-11-08","current":4.056395,"twenty":-5.990937,"median":-3.497588,"eighty":-0.594406,"marketCap":70804372},{"date":"2024-11-15","current":3.870606,"twenty":-5.990937,"median":-3.48159,"eighty":-0.578927,"marketCap":67561423},{"date":"2024-11-22","current":18.467582,"twenty":-5.990937,"median":-3.470102,"eighty":-0.458144,"marketCap":64876616},{"date":"2024-11-29","current":17.691633,"twenty":-5.990937,"median":-3.457398,"eighty":-0.423147,"marketCap":62150708},{"date":"2024-12-06","current":18.002013,"twenty":-5.990937,"median":-3.43318,"eighty":-0.381786,"marketCap":63241071},{"date":"2024-12-13","current":17.070874,"twenty":-5.990937,"median":-3.422585,"eighty":-0.359516,"marketCap":59969981},{"date":"2024-12-20","current":15.487939,"twenty":-5.990937,"median":-3.404992,"eighty":-0.334353,"marketCap":54409128},{"date":"2024-12-27","current":14.648362,"twenty":-5.990937,"median":-3.386446,"eighty":-0.330882,"marketCap":51459695},{"date":"2025-01-03","current":16.760495,"twenty":-5.990937,"median":-3.370704,"eighty":-0.318874,"marketCap":58879618},{"date":"2025-01-10","current":15.518977,"twenty":-5.995124,"median":-3.345397,"eighty":-0.303395,"marketCap":54518165},{"date":"2025-01-17","current":12.956793,"twenty":-5.995124,"median":-3.326307,"eighty":-0.29671,"marketCap":45517215},{"date":"2025-01-24","current":13.513925,"twenty":-5.995124,"median":-3.295829,"eighty":-0.285503,"marketCap":47474418},{"date":"2025-01-31","current":13.50151,"twenty":-5.995124,"median":-3.259228,"eighty":-0.278399,"marketCap":47430803},{"date":"2025-02-07","current":13.397532,"twenty":-5.995124,"median":-3.238556,"eighty":-0.271439,"marketCap":47065531},{"date":"2025-02-14","current":12.674348,"twenty":-5.995124,"median":-3.20854,"eighty":-0.261142,"marketCap":44524985},{"date":"2025-02-21","current":12.984728,"twenty":-5.995124,"median":-3.176076,"eighty":-0.253659,"marketCap":45615348},{"date":"2025-02-28","current":12.10325,"twenty":-5.995124,"median":-3.155249,"eighty":-0.248371,"marketCap":42518716},{"date":"2025-03-07","current":12.228954,"twenty":-5.999311,"median":-3.12706,"eighty":-0.245393,"marketCap":42960314},{"date":"2025-03-14","current":12.081523,"twenty":-5.999311,"median":-3.115449,"eighty":-0.2427,"marketCap":42442391},{"date":"2025-03-21","current":12.067556,"twenty":-5.999311,"median":-3.115449,"eighty":-0.238173,"marketCap":42393325},{"date":"2025-03-28","current":13.347872,"twenty":-5.999311,"median":-3.115449,"eighty":-0.222173,"marketCap":46891073},{"date":"2025-04-04","current":-0.508736,"twenty":-5.999311,"median":-3.115449,"eighty":-0.222173,"marketCap":34881999},{"date":"2025-04-11","current":-0.470825,"twenty":-5.995124,"median":-3.113595,"eighty":-0.223574,"marketCap":32282620},{"date":"2025-04-17","current":-0.603309,"twenty":-5.995124,"median":-3.113595,"eighty":-0.223574,"marketCap":41366474}],"updateTime":1745134121109}}}